Revive is a clinical-stage company focused on commercializing treatments for Gout and orphan drug indications such as, Cystinuria, Wilson disease and Rett syndrome. Revive’s business model employs a lower risk drug development and commercial strategy by focusing on finding new uses of old drugs through drug repurposing with the objective of finding an appropriate partner or partners to bring the new use drug to the marketplace.
Bruce N. Cronstein, MD, Joins Revive Therapeutics as Medical Advisor
Revive Therapeutics Enters Into Advisory Agreement with Spinnaker Capital Markets Inc.
Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease
Revive Therapeutics Announces Results for the Three and Six Months Ended December 31, 2014